Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma
- 14 November 2019
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Clinical Pharmacology
- Vol. 12 (12), 1107-1119
- https://doi.org/10.1080/17512433.2019.1689121
Abstract
Introduction: Melanoma in-transit metastases (ITMs) occur between the primary tumor site and the regional node field. Most patients with ITMs have a poor prognosis. The treatment of ITMs can be simple if surgical excision is possible, but challenging when ITMs are advanced, multiple or recurrent and impacting quality of life. Areas covered: The management of ITM is still evolving. Patients who are disease-free after surgical excision of ITMs are today candidates for adjuvant systemic treatment to reduce recurrence risk. Some who have multiple or advanced ITMs may achieve long-term survival or disease control with systemic therapies alone. Those who do not remain candidates for the numerous locoregional therapies used to treat ITMs, including electrocautery, intralesional injection, topical therapy, electrochemotherapy, isolated limb infusion, isolated limb perfusion, radiation therapy and, rarely, amputation. Relevant publications identified in Pubmed and MEDLINE databases are reviewed. Expert opinion: Patients with multiple ITMs can benefit from use of systemic therapies as primary treatment, in the adjuvant setting and in neoadjuvant trials. Multiple alternative treatment modalities exist for patients unsuitable for systemic therapies or in whom systemic therapies have failed. Trials assessing combined systemic and locoregional therapies for ITMs are in progress.Keywords
This publication has 124 references indexed in Scilit:
- Intralesional Injection of Rose Bengal Induces a Systemic Tumor-Specific Immune Response in Murine Models of Melanoma and Breast CancerPLOS ONE, 2013
- Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III DiagnosisPLOS ONE, 2013
- Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activationOncoImmunology, 2012
- Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanomaJournal of Translational Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other TumorsCancer Biotherapy & Radiopharmaceuticals, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Isolated Limb Perfusion for Malignant Melanoma: Systematic Review on Effectiveness and SafetyThe Oncologist, 2010
- Treatment of extensive cutaneous metastatic melanoma with topical diphencyproneJournal of the American Academy of Dermatology, 2007
- Sentinel-Node Biopsy or Nodal Observation in MelanomaNew England Journal of Medicine, 2006